<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04296695</url>
  </required_header>
  <id_info>
    <org_study_id>Gilead ISR-CN-18-10596</org_study_id>
    <nct_id>NCT04296695</nct_id>
  </id_info>
  <brief_title>Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection</brief_title>
  <official_title>The Efficacy and Safety of Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy and safety of Biktarvy in Treatment-Naïve Late Presenters with HIV-1 Infection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV epidemic is still severe in China, the estimated number if PLWH in HIV is around 1.25
      million all of China with an increasing trend of new cases. Late presenters with low CD4 T
      cells and/or with hight viral load should be paid more attention for better treatment and
      care. As a new combined antiretroviral regimen of integrase inhibitor, B/F/TAF was recently
      approved in US and European and also in China which needs more real world data in China.
      Non-inferiority or advantage of B/F/TAF comparing with the first line TDF/3TC/EFV for later
      presenters in China needs to be explored.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Non-inferioty or advantage of B/F/TAF comparing with the first line TDF/3TC/EFV for later presenters in China</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>randomized, multicentered, open-lable RCT, one arm with B/F/TAF and one arm with TDF/3TC/EFV</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with HIV-1 RNA</measure>
    <time_frame>Weeks 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Change in CD4 T cell count from baseline</measure>
    <time_frame>Weeks 12, 24 and 48</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>B/F/TAF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50mg/600mg/300mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TDF/3TC/EFV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>300mg/300mg/400mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B/F/TAF</intervention_name>
    <description>randomized, multicentered, open-lable RCT, one arm with B/F/TAF and one arm with TDF/3TC/EFV</description>
    <arm_group_label>B/F/TAF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TDF/3TC/EFV</intervention_name>
    <description>TDF/3TC/EFV</description>
    <arm_group_label>TDF/3TC/EFV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.Ability to understand and sign a written informed consent form 2.18 years old or older
        3.Confirmed HIV-antibody positive through Western Blot testing without any previous ART
        4.CD4 &lt; 200/mm3, VL &gt;1000 copies/ml 5.Estimated glomerular filtration rate (GFR) ≥ 50
        mL/min (calculated by CKD-EPI) 6.Clinical status relatively stable 7.Females of
        childbearing potential must agree to utilize highly effective contraception methods or be
        non-heterosexually from screening throughout the duration of study treatment and for 30
        days following the last dose of study drug.

        Exclusion Criteria:

          1. A new AIDS-defining condition diagnosed within the 30 days prior to screening

          2. Participants experiencing severe organ lesion.

          3. Positive serum pregnancy test or planned to be pregnant.

          4. Females who are breastfeeding

          5. With carcinoma

          6. Concomitant medication of immunosuppression or chemoradiotherapy

          7. Participation in any other interventional clinical trial

          8. Screening stage find: Hb &lt; 9g/dL, WBC &lt; 3000/ul. neutrophilic granulocyte&lt; 1500/ul,
             PLT&lt; 75000/ul. Scr &gt; 1.5 ULN,Hepatic transaminases (AST and ALT) and ALP &gt; 3 ×
             ULN,total bilirubin ≤ 2 x ULN.

          9. Any other clinical condition or prior therapy that, in the opinion of the
             Investigator, would make the subject unsuitable for the study or unable to comply with
             dosing requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Lyu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Infectious Diseases, PekingUMCH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei Lyu</last_name>
    <phone>+8613501385800</phone>
    <email>lvweipumch@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qing Zhang</last_name>
    <phone>+13207572893</phone>
    <email>zhangqingpumch@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Guangxi Zhuang Autonomous Region Longtan Hospital</name>
      <address>
        <city>Liuzhou</city>
        <state>Guangxi</state>
        <zip>545005</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>RUICHAO LU</last_name>
      <phone>+8613607825966</phone>
      <email>ruichaolu@163.com</email>
    </contact>
    <investigator>
      <last_name>RUICHAO LU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guiyang Public Health Clinic Center</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <zip>550004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Nanjing</name>
      <address>
        <city>Najing</city>
        <state>Jiangsu</state>
        <zip>210003</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>HONGXIA WEI</last_name>
      <phone>+8613851507368</phone>
      <email>wghongxia@sina.com</email>
    </contact>
    <investigator>
      <last_name>HONGXIA WEI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xi'an Number Eight Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>JUAN JIN</last_name>
      <phone>+8613484906957</phone>
      <email>13484906957@163.com</email>
    </contact>
    <investigator>
      <last_name>JUAN JIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Second People's Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300192</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>PING MA</last_name>
      <phone>+8615922124490</phone>
      <email>mapingtianjin@163.com</email>
    </contact>
    <investigator>
      <last_name>PING MA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 3, 2020</study_first_submitted>
  <study_first_submitted_qc>March 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biktarvy</keyword>
  <keyword>HIV-1 infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

